PE20142432A1 - Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21 - Google Patents

Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21

Info

Publication number
PE20142432A1
PE20142432A1 PE2014001980A PE2014001980A PE20142432A1 PE 20142432 A1 PE20142432 A1 PE 20142432A1 PE 2014001980 A PE2014001980 A PE 2014001980A PE 2014001980 A PE2014001980 A PE 2014001980A PE 20142432 A1 PE20142432 A1 PE 20142432A1
Authority
PE
Peru
Prior art keywords
growth factor
proteins
fibroblast growth
therapeutic uses
fibroblasto
Prior art date
Application number
PE2014001980A
Other languages
English (en)
Inventor
Yanfei Linda Ma
Rovira Armando Rafael Irizarry
Vincent Louis Reynolds
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142432(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20142432A1 publication Critical patent/PE20142432A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A LA PROTEINA DEL FACTOR DE CRECIMIENTO DE FIBROBLASTO 21 HUMANO (FGF21) DE LA SEC ID NO: 1, OPCIONALMENTE EN COMBINACION CON OTRA AGENTE ACTIVO. UTIL EN EL INCREMENTO DE LA FORMACION OSEA.
PE2014001980A 2012-05-15 2013-05-09 Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21 PE20142432A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US201361786939P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20142432A1 true PE20142432A1 (es) 2015-01-22

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001980A PE20142432A1 (es) 2012-05-15 2013-05-09 Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21

Country Status (21)

Country Link
US (1) US20150141335A1 (es)
EP (1) EP2852398A1 (es)
JP (1) JP2015522539A (es)
KR (1) KR20150002801A (es)
CN (1) CN104302311A (es)
AU (1) AU2013263188A1 (es)
BR (1) BR112014028413A2 (es)
CA (1) CA2869320A1 (es)
CL (1) CL2014002846A1 (es)
CO (1) CO7131381A2 (es)
EA (1) EA201491856A1 (es)
HK (1) HK1202800A1 (es)
IL (1) IL235482A0 (es)
MA (1) MA37506B1 (es)
MX (1) MX2014013913A (es)
PE (1) PE20142432A1 (es)
PH (1) PH12014502537A1 (es)
SG (1) SG11201407655TA (es)
TN (1) TN2014000409A1 (es)
WO (1) WO2013173158A1 (es)
ZA (1) ZA201407532B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113683705A (zh) 2011-07-01 2021-11-23 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
CN105828878A (zh) 2013-10-28 2016-08-03 恩格姆生物制药公司 癌症模型及相关方法
SG11201606018UA (en) 2014-01-24 2016-08-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016039339A1 (ja) * 2014-09-08 2016-03-17 国立大学法人大阪大学 脱髄疾患の予防又は治療剤
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121563A2 (en) * 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos

Also Published As

Publication number Publication date
SG11201407655TA (en) 2014-12-30
KR20150002801A (ko) 2015-01-07
HK1202800A1 (en) 2015-10-09
US20150141335A1 (en) 2015-05-21
JP2015522539A (ja) 2015-08-06
MA37506B1 (fr) 2017-03-31
TN2014000409A1 (en) 2015-12-21
AU2013263188A1 (en) 2014-10-16
MA37506A1 (fr) 2016-01-29
WO2013173158A1 (en) 2013-11-21
EA201491856A1 (ru) 2015-03-31
BR112014028413A2 (pt) 2017-11-07
IL235482A0 (en) 2014-12-31
CN104302311A (zh) 2015-01-21
ZA201407532B (en) 2016-05-25
EP2852398A1 (en) 2015-04-01
MX2014013913A (es) 2015-02-17
PH12014502537A1 (en) 2015-01-21
CL2014002846A1 (es) 2015-01-30
CO7131381A2 (es) 2014-12-01
CA2869320A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
PE20142432A1 (es) Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201492053A1 (ru) Белки фактора роста фибробластов 21
ECSP13013097A (es) Coagonistas del receptor de glucagón/glp-1
MX2020010399A (es) 3-epimerasa.
PE20142044A1 (es) Variantes del factor 21 del crecimiento de fibroblastos
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
MX342313B (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CO7131377A2 (es) Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos
NZ707016A (en) Glycoprotein hormone long-acting superagonists
PE20160848A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
MX2016005973A (es) Superagonistas de acción prolongada de la hormona de glicoproteína.
MX2015006779A (es) Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
PL405043A1 (pl) Preparat wspomagający naturalną odporność organizmu
CR20130685A (es) Coagonistas del receptor de guacon /glp-1
MD4291B1 (ro) Preparat medicamentos pentru tratamentul otitelor
UA103987C2 (ru) Способ терновской т.а. лечения варикозной болезни детей

Legal Events

Date Code Title Description
FD Application declared void or lapsed